(19)
(11) EP 3 458 473 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.08.2022 Bulletin 2022/33

(45) Mention of the grant of the patent:
13.04.2022 Bulletin 2022/15

(21) Application number: 17725914.0

(22) Date of filing: 15.05.2017
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
G01N 33/50(2006.01)
 C07K 16/28(2006.01)
C12N 5/0783(2010.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/4748; C12N 5/0637; A61P 35/00; A61P 35/04; A61P 37/04; A61P 43/00
(86) International application number:
PCT/EP2017/061642
(87) International publication number:
WO 2017/198631 (23.11.2017 Gazette 2017/47)

(54)

MARKERS SELECTIVELY DEREGULATED IN TUMOR-INFILTRATING REGULATORY T CELLS.

SELEKTIV DEREGULIERTE MARKERMOLEKÜLEN IN TUMOR-INFILTRIERENDEN REGULIERENDE T-ZELLEN

MARQUEURS SÉLECTIVEMENT DEREGULÉS DANS LES CELLULES T RÉGULATRICES PRÉSENTES DANS LES INFILTRTIONS TUMORALES.

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.05.2016 EP 16169791
14.11.2016 EP 16198724

(43) Date of publication of application:
27.03.2019 Bulletin 2019/13

(60) Divisional application:
22159825.3

(73) Proprietor: CHECKMAB S.R.L.
20129 Milano (IT)

(72) Inventors:
  • ABRIGNANI, Sergio
    53040 Rapolano Terme (SI) (IT)
  • PAGANI, Massimiliano
    24069 Trescore Balneario (BG) (IT)

(74) Representative: HGF 
HGF Limited 1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)


(56) References cited: : 
WO-A2-2007/044756
WO-A2-2009/100035
 WO-A2-2007/044756
WO-A2-2009/100035
   
  • FEHRENBACHER L. ET AL.: "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", THE LANCET, vol. 387, no. 10030, 9 March 2016 (2016-03-09), pages 1837-1846, XP002796570,
  • BHAIRAVABHOTLA R. ET AL: "Transcriptome profiling of human FoxP3+regulatory T cells", HUMAN IMMUNOLOGY, vol. 77, no. 2, 10 December 2015 (2015-12-10), pages 201-213, XP029421993,
  • PLITAS G. ET AL: "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, vol. 76, no. 4 Supplement, 15 February 2016 (2016-02-15), page P4-04-11, XP055396219, US
  • GUAY S. & AKOUM A.: "Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology", REPRODUCTION, vol. 134, no. 3, September 2007 (2007-09), pages 525-534, XP002796571,
  • MAR A.C. ET AL.: "Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis", J. BIOL. CHEM., vol. 290, no. 36, 4 September 2015 (2015-09-04), pages 22212-22224, XP002796572,
  • TOSOLINI M. ET AL.: "Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.", CANCER RES., vol. 71, no. 4, 8 February 2011 (2011-02-08), pages 1263-1271, XP002796573,
  • MARABELLE A ET AL: "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 123, no. 6, 1 June 2013 (2013-06-01), pages 2447-2463, XP002759891, ISSN: 0021-9738, DOI: 10.1172/JCI64859 [retrieved on 2013-05-24]
  • TAKEUCHI Y. ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 9 May 2016 (2016-05-09), pages 401-409, XP055396222,
  • SELBY M.J. ET AL: "Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 1, no. 1, 7 April 2013 (2013-04-07), pages 32-42, XP055100395, DOI: 10.1158/2
  • MARABELLE A ET AL: "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 123, no. 6, 1 June 2013 (2013-06-01), pages 2447-2463, XP002759891, ISSN: 0021-9738, DOI: 10.1172/JCI64859 [retrieved on 2013-05-24] cited in the application
  • G PLITAS ET AL: "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, vol. 76, no. 4 Supplement, 15 February 2016 (2016-02-15), pages P4-04-11-P4-04-11, XP055396219, & 103RD ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; CHICAGO, IL, USA; MARCH 31 -APRIL 04, 2012 ISSN: 0008-5472, DOI: 10.1158/1538-7445.SABCS15-P4-04-11
  • YOSHIKO TAKEUCHI ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 9 May 2016 (2016-05-09), pages 401-409, XP055396222, ISSN: 0953-8178, DOI: 10.1093/intimm/dxw025
  • BHAIRAVABHOTLA RAVIKIRAN ET AL: "Transcriptome profiling of human FoxP3+regulatory T cells", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 77, no. 2, 10 December 2015 (2015-12-10), pages 201-213, XP029421993, ISSN: 0198-8859, DOI: 10.1016/J.HUMIMM.2015.12.004
  • PLITAS GEORGE ET AL: "Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer", IMMUNITY, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1122-1134, XP029809259, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2016.10.032
  • DE SIMONE MARCO ET AL: "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", IMMUNITY, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1135-1147, XP029809250, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2016.10.021
  • BHAIRAVABHOTLA R. ET AL: "Transcriptome profiling of human FoxP3+regulatory T cells", HUMAN IMMUNOLOGY, vol. 77, no. 2, 10 December 2015 (2015-12-10), pages 201-213, XP029421993,
  • FEHRENBACHER L. ET AL.: "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", THE LANCET, vol. 387, no. 10030, 9 March 2016 (2016-03-09), pages 1837-1846, XP002796570,
  • SELBY M.J. ET AL: "Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 1, no. 1, 7 April 2013 (2013-04-07), pages 32-42, XP055100395, DOI: 10.1158/2
  • TAKEUCHI Y. ET AL: "Roles of regulatory T cells in cancer immunity", INTERNATIONAL IMMUNOLOGY, vol. 28, no. 8, 9 May 2016 (2016-05-09), pages 401-409, XP055396222,
  • MARABELLE A ET AL: "Depleting tumor-specific Tregs at a single site eradicates disseminated tumors", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 123, no. 6, 1 June 2013 (2013-06-01), pages 2447-2463, XP002759891, ISSN: 0021-9738, DOI: 10.1172/JCI64859 [retrieved on 2013-05-24]
  • MAR A.C. ET AL.: "Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis", J. BIOL. CHEM., vol. 290, no. 36, 4 September 2015 (2015-09-04), pages 22212-22224, XP002796572,
  • GUAY S. & AKOUM A.: "Stable inhibition of interleukin 1 receptor type II in Ishikawa cells augments secretion of matrix metalloproteinases: possible role in endometriosis pathophysiology", REPRODUCTION, vol. 134, no. 3, September 2007 (2007-09), pages 525-534, XP002796571,
  • PLITAS G. ET AL: "Abstract P4-04-11: Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target", CANCER RESEARCH, vol. 76, no. 4 Supplement, 15 February 2016 (2016-02-15), page P4-04-11, XP055396219, US
  • TOSOLINI M. ET AL.: "Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.", CANCER RES., vol. 71, no. 4, 8 February 2011 (2011-02-08), pages 1263-1271, XP002796573,
  • DE SIMONE MARCO ET AL: "Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells", IMMUNITY, CELL PRESS, AMSTERDAM, NL, vol. 45, no. 5, 15 November 2016 (2016-11-15), pages 1135-1147, XP029809250, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2016.10.021
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).